Lundbeck/Takeda’s Brintellix Passes Muster In Three Of Four Pivotal Trials
The multimodal antidepressant Brintellix (vortioxetine), now pending at FDA, has an intriguing mechanism of action that hits a number of receptors, which in theory could translate into better effects. But in studies presented at the APA meeting, its efficacy and safety looked on par with other antidepressants.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.